Edwards Lifesciences (EW) Cash Flow Statement

Click line-items for a historical chart and %

Net income
Depreciation and amortization	52.1M
Stock-based compensation (Note 10)	43M
Excess tax benefit from stock plans	-56.6M
Deferred income taxes	-2.6M
Special charges, net (Note 2)
Other	6.3M
Accounts and other receivables, net	-54.8M
Inventories, net	-43.1M
Accounts payable and accrued liabilities	41.4M
Prepaid expenses and other current assets	-14.5M
Other	16.1M
Net cash provided by operating activities
Capital expenditures	-112.9M
Acquisition (Note 4)	0
Proceeds from (investments in) unconsolidated affiliates, net
Proceeds from sale of assets
Proceeds from (investments in) trading securities, net
Investments in intangible assets	-41.3M
Other	700K
Net cash used in investing activities
Proceeds from issuance of debt
Payments on debt
Purchases of treasury stock	-380.9M
Proceeds from stock plans	82.7M
Excess tax benefit from stock plans	56.6M
Other	4.1M
Net cash provided by (used in) financing activities
Effect of currency exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents	-73.4M
Cash and cash equivalents at beginning of period	718.4M
Cash and cash equivalents at end of period	645M
Distribution of treasury shares to effect stock split

Entities mentioned with EW

View All Entities